Bio-Rad Laboratories Inc Stock News

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ATNI, ABR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2023.

The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.

Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Bio-Rad (BIO) continues to experience weak demand for Life Science products in China.

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $3.10 per share, beating the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $3.31 per share a year ago.

Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for th

Bio-Rad's (BIO) margin performance suffers due to elevated raw material costs, increased logistics costs and higher employee-related expenses.

The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q3 2023 Results Conference Call October 26, 2023 5:00 PM ET Company Participants Edward Chung - Head, IR Norman Schwartz - CEO Ilan Daskal - EVP and CFO Andy Las

Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BIO, LPG and COLB have been added to the Zacks Rank #5 (Strong Sell) List on September 19, 2023.